Stereotactic body radiotherapy ‘on the rise’ for HCC
Data from 10 Australian centres provides a snapshot of diverse practice in adoption of the emerging therapy
Stereotactic body radiation therapy is being increasingly used to treat hepatocellular carcinoma in Australia, but patient selection and dosing schedules vary widely, radiation oncologists say.
Their study shows that the emerging ablative therapy is being chosen first-line, for salvage after cancer recurrence, and as palliative therapy in patients with a range of tumour sizes and stages.